Discover open access scientific publications

Search, annotate, share and cite publications

Publications by JEN-FU SHIH

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

Experimental and Therapeutic Medicine

English

Related publications

P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations With Non-Adenocartinoma Histology

Journal of Thoracic Oncology

English

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma

Pathology and Oncology Research

English

OA07.06 Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.

Journal of Thoracic Oncology

English

P1.01-43 Next-Generation Sequencing in the Exploration of Genetic Heterogeneity for Lung Adenocarcinoma Patients With EGFR Activating Mutations

Journal of Thoracic Oncology

English

Pemetrexed Had Significantly Better Clinical Efficacy in Patients With Stage IV Lung Adenocarcinoma With Susceptible EGFR Mutations Receiving Platinum-Based Chemotherapy After Developing Resistance to the First-Line Gefitinib Treatment

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

P2.13-11 EGFR Amplification and Sensitizing Mutations Correlates With Survival From Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP¶)

Journal of Thoracic Oncology

English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

English

OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients With EGFR Activating and T790M Mutations

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by JEN-FU SHIH

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

Related publications

P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations With Non-Adenocartinoma Histology

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma

OA07.06 Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.

P1.01-43 Next-Generation Sequencing in the Exploration of Genetic Heterogeneity for Lung Adenocarcinoma Patients With EGFR Activating Mutations

Pemetrexed Had Significantly Better Clinical Efficacy in Patients With Stage IV Lung Adenocarcinoma With Susceptible EGFR Mutations Receiving Platinum-Based Chemotherapy After Developing Resistance to the First-Line Gefitinib Treatment

P2.13-11 EGFR Amplification and Sensitizing Mutations Correlates With Survival From Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP¶)

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients With EGFR Activating and T790M Mutations